Summary

The majority of vectors used for gene therapies are currently generated using transient production systems, primarily due to convenience and speed of process. Manufacturing viral vectors via transient transfection is flexible and efficient and does not require time consuming development of stable cell lines. However, transfection based methods do require optimization to ensure the highest productivity, consistency between batches, and scalability.

Key areas for improvement of transfection in AAV production :

  • Identify and address common bottlenecks to scalable transfections.
  • Streamline the scale-up and transfection process.
  • Design and standardize the process for consistent, reproducible results.
  • Maintain actively dividing cells and cell culture health for efficient transfections.

Download our White Paper: “Ask the Expert – Transfection Best Practices for AAV Gene Therapy”.

Ask the Expert Polyplus Corning

 

Give your feedback!